Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.

doi:10.1200/JCO.23.00152

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 10 Sept 2023

Piotrowska Zofia, Tan Daniel Shao-Weng, Smit Egbert F, Spira Alexander I, Soo Ross A, Nguyen Danny, Lee Victor Ho-Fun, Yang James Chih-Hsin, Velcheti Vamsidhar, Wrangle John M, Socinski Mark A, Koczywas Marianna, Janik John E, Jones Jeffrey, Yu Helena Alexandra

Abstract excerpt

PURPOSE: Although several agents targeting epidermal growth factor receptor (EGFR) exon 20 insertions (ex20ins) have recently been approved by the US Food and Drug Administration, toxicities related to the inhibition of wild-type (WT) EGFR are common with these agents and affect overall tolerability. Zipalertinib (CLN-081, TAS6417) is an oral EGFR tyrosine kinase inhibitor (TKI) with a novel pyrrolopyrimidine...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Diarrhea

Share to ErbB Receptors

Share to Exons

Share to EGFR gene

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Source

Open in PubMed

Identifiers

PMID: 37384848
DOI: 10.1200/JCO.23.00152

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions.PMID 37384848Read ↗

REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with EGFR exon 20 insertion-mutated NSCLC.Semantic proximity Read ↗

Zipalertinib in Patients With Epidermal Growth Factor Receptor Exon 20 Insertion-Positive Non–Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy With or Without AmivantamabSemantic proximity Read ↗

Zipalertinib—A Novel Treatment Opportunity for Non-Small Cell Lung Cancers with Exon 20 Insertions and Uncommon EGFR MutationsSemantic proximity Read ↗

Analysis of the efficacy and influencing factors of double-dose furmonertinib for advanced EGFR ex20ins non-small cell lung cancer.Semantic proximity Read ↗

Response to Standard Therapies and Comprehensive Genomic Analysis for Patients with Lung Adenocarcinoma with EGFR Exon 20 Insertions.Semantic proximity Read ↗

Therapeutic Advances in Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations: From Molecular Biology to Targeted Therapy.Semantic proximity Read ↗

Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.Semantic proximity Read ↗

Mobocertinib in Patients with EGFR Exon 20 Insertion-Positive Non-Small Cell Lung Cancer (MOON): An International Real-World Safety and Efficacy AnalysisSemantic proximity Read ↗

Characterization and management of adverse events observed with mobocertinib (TAK-788) treatment for EGFR exon 20 insertion-positive non-small cell lung cancer.Semantic proximity Read ↗

FDA Approval Summary: Mobocertinib for Metastatic Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.Semantic proximity Read ↗

Poziotinib in Treatment-Naive NSCLC Harboring HER2 Exon 20 Mutations: ZENITH20-4, A Multicenter, Multicohort, Open-Label, Phase 2 Trial (Cohort 4).Semantic proximity Read ↗

Mobocertinib: Mechanism of action, clinical, and translational science.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.